Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.

Alexander M, Pavlakis N, John T, O'Connell R, Kao S, Hughes BGM, Lee A, Hayes SA, Howell VM, Clarke SJ, Millward M, Burbury K, Solomon B, Itchins M.

Lung Cancer. 2020 Jan 22;142:34-40. doi: 10.1016/j.lungcan.2020.01.017. [Epub ahead of print]

PMID:
32087434
2.

The Economic Impact on Australian Patients with Neuroendocrine Tumours.

Gordon LG, Elliott TM, Wakelin K, Leyden S, Leyden J, Michael M, Pavlakis N, Mumford J, Segelov E, Wyld DK.

Patient. 2020 Feb 19. doi: 10.1007/s40271-020-00412-z. [Epub ahead of print]

PMID:
32072460
3.

Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer.

Sahni S, Moon EA, Howell VM, Mehta S, Pavlakis N, Chan D, Ahadi MS, Gill AJ, Samra J, Mittal A.

Eur J Surg Oncol. 2020 Feb 6. pii: S0748-7983(20)30070-6. doi: 10.1016/j.ejso.2020.02.001. [Epub ahead of print]

PMID:
32061458
4.

The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.

Lung MS, Hicks RJ, Pavlakis N, Link E, Jefford M, Thomson B, Wyld DK, Liauw W, Akhurst T, Kuru N, Michael M.

Asia Pac J Clin Oncol. 2020 Feb 7. doi: 10.1111/ajco.13307. [Epub ahead of print]

PMID:
32030887
5.

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma.

Itchins M, Chua TC, Arena J, Jamieson NB, Nahm CB, OʼConnell RL, Bailey EA, Schembri GP, Gill AJ, Kneebone A, Hruby G, Mittal A, Pavlakis N, Clarke SJ, Samra JS.

Pancreas. 2020 Feb;49(2):224-229. doi: 10.1097/MPA.0000000000001472.

PMID:
32011525
6.

Targeting BRAF mutations in non-small cell lung cancer.

O'Leary CG, Andelkovic V, Ladwa R, Pavlakis N, Zhou C, Hirsch F, Richard D, O'Byrne K.

Transl Lung Cancer Res. 2019 Dec;8(6):1119-1124. doi: 10.21037/tlcr.2019.10.22. Review.

7.

Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer.

Chan JCY, Diakos CI, Engel A, Chan DLH, Pavlakis N, Gill A, Clarke SJ.

PLoS One. 2020 Jan 30;15(1):e0228466. doi: 10.1371/journal.pone.0228466. eCollection 2020.

8.

Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention.

Guccione L, Gough K, Drosdowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P.

JMIR Res Protoc. 2019 Dec 3;8(12):e14361. doi: 10.2196/14361.

9.

Mass Cytometry Reveals a Sustained Reduction in CD16+ Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients.

Shinko D, McGuire HM, Diakos CI, Pavlakis N, Clarke SJ, Byrne SN, Charles KA.

Front Immunol. 2019 Nov 5;10:2584. doi: 10.3389/fimmu.2019.02584. eCollection 2019.

10.

High metabolic tumour volume on FDG PET predicts poor survival from neuroendocrine neoplasms.

Chan DL, Bernard E, Schembri G, Roach P, Johnson M, Pavlakis N, Clarke SJ, Bailey D.

Neuroendocrinology. 2019 Nov 12. doi: 10.1159/000504673. [Epub ahead of print]

PMID:
31711058
11.

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.

Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S.

Pathology. 2019 Dec;51(7):673-680. doi: 10.1016/j.pathol.2019.08.006. Epub 2019 Oct 24.

PMID:
31668406
12.

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.

Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S.

Lung Cancer. 2019 Dec;138:79-87. doi: 10.1016/j.lungcan.2019.10.002. Epub 2019 Oct 11.

PMID:
31654838
13.

Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care.

Woodhouse B, Pattison S, Segelov E, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Michael M, Wakelin K, Asif T, Lo D, Price T, Lawrence B; Commonwealth Neuroendocrine Tumour Collaboration (CommNETs).

J Clin Med. 2019 Sep 12;8(9). pii: E1455. doi: 10.3390/jcm8091455.

14.

Reply to K. Masuda et al.

Fennell DA, Taylor P, Gilligan D, Nakano T, Scherpereel A, Pavlakis N, van Meerbeeck JP, Aerts JGJV, Nowak AK, Kindler H, Baas P.

J Clin Oncol. 2019 Sep 1;37(25):2294-2295. doi: 10.1200/JCO.19.01208. Epub 2019 Jul 22. No abstract available.

PMID:
31329517
15.

Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study.

Chan JCY, Diakos CI, Engel A, Chan DLH, Pavlakis N, Gill A, Clarke SJ.

PLoS One. 2019 Jun 12;14(6):e0218207. doi: 10.1371/journal.pone.0218207. eCollection 2019.

16.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15.

PMID:
31103412
17.

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.

O'Leary C, Xu W, Pavlakis N, Richard D, O'Byrne K.

Cancers (Basel). 2019 May 3;11(5). pii: E620. doi: 10.3390/cancers11050620. Review.

18.

Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.

Vasista A, Stockler M, Martin A, Pavlakis N, Sjoquist K, Goldstein D, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Nott L, Snow S, Burge M, Harris D, Jonker D, Chua YJ, Epstein R, Bonaventura A, Kiely B.

Oncologist. 2019 Nov;24(11):e1102-e1107. doi: 10.1634/theoncologist.2018-0613. Epub 2019 Apr 1.

19.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.

J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20. Erratum in: J Thorac Oncol. 2019 Nov;14(11):2023.

20.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.

PMID:
30785827
21.

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Reck M, Kerr KM, Grohé C, Manegold C, Pavlakis N, Paz-Ares L, Huber RM, Popat S, Thatcher N, Park K, Hilberg F, Barrueco J, Kaiser R.

Future Oncol. 2019 Apr;15(12):1363-1383. doi: 10.2217/fon-2018-0948. Epub 2019 Feb 13. Review.

22.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT.

Eur J Cancer. 2019 Mar;109:28-35. doi: 10.1016/j.ejca.2018.11.030. Epub 2019 Jan 24.

PMID:
30685684
23.

Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Sud S, O'Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, Tu D, Goodwin R.

Curr Oncol. 2018 Dec;25(6):e516-e526. doi: 10.3747/co.25.4069. Epub 2018 Dec 1.

24.

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT.

J Natl Cancer Inst. 2019 Jun 1;111(6):575-583. doi: 10.1093/jnci/djy156.

25.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

26.

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E.

Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.

PMID:
30463680
27.

New drug developments in metastatic gastric cancer.

Tan AC, Chan DL, Faisal W, Pavlakis N.

Therap Adv Gastroenterol. 2018 Nov 14;11:1756284818808072. doi: 10.1177/1756284818808072. eCollection 2018. Review.

28.

Correction to: The role of proteomics in the age of immunotherapies.

Hayes SA, Clarke S, Pavlakis N, Howell VM.

Mamm Genome. 2018 Dec;29(11-12):770. doi: 10.1007/s00335-018-9785-0.

PMID:
30370456
29.

Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.

Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, Arena J, Colvin E, Howell VM, Pavlakis N, Clarke S, Samra JS, Gill AJ, Mittal A.

Eur J Surg Oncol. 2019 Feb;45(2):218-224. doi: 10.1016/j.ejso.2018.10.050. Epub 2018 Oct 11.

PMID:
30348604
30.

The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer.

Lane RJ, Khin NY, Rogan CM, Magnussen JS, Ho-Shon K, Pavlakis N, Clarke SJ, Hugh TJ.

J Control Release. 2018 Dec 28;292:18-28. doi: 10.1016/j.jconrel.2018.10.019. Epub 2018 Oct 19. Review.

31.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.

32.

Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.

Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group.

JAMA Oncol. 2018 Nov 1;4(11):1597-1604. doi: 10.1001/jamaoncol.2018.2428.

PMID:
30054622
33.

The role of proteomics in the age of immunotherapies.

Hayes SA, Clarke S, Pavlakis N, Howell VM.

Mamm Genome. 2018 Dec;29(11-12):757-769. doi: 10.1007/s00335-018-9763-6. Epub 2018 Jul 25. Review. Erratum in: Mamm Genome. 2018 Oct 29;:.

PMID:
30046851
34.

Targeted therapy for metastatic colorectal cancer.

Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J.

Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664. Epub 2018 Aug 3. Review.

PMID:
30019590
35.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):362.

36.

ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.

Lee A, Howell VM, Itchins M, Wheeler HR, Pavlakis N.

Clin Lung Cancer. 2018 Sep;19(5):457-459. doi: 10.1016/j.cllc.2018.05.015. Epub 2018 Jun 5. No abstract available.

PMID:
29945753
37.

Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions.

Oh B, Yeung A, Klein P, Larkey L, Ee C, Zaslawski C, Knobf T, Payne P, Stener-Victorin E, Lee R, Choi W, Chun M, Bonucci M, Lang HD, Pavlakis N, Boyle F, Clarke S, Back M, Yang P, Wei Y, Guo X, Weng CD, Irwin MR, Elfiky AA, Rosenthal D.

Medicines (Basel). 2018 Jun 8;5(2). pii: E51. doi: 10.3390/medicines5020051.

38.

Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity.

Brown KM, Xue A, Julovi SM, Gill AJ, Pavlakis N, Samra JS, Smith RC, Hugh TJ.

J Surg Res. 2018 Jul;227:158-167. doi: 10.1016/j.jss.2018.02.018. Epub 2018 Mar 15.

PMID:
29804848
39.

Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.

Itchins M, Hayes SA, Gill AJ, Cooper W, O'Connell R, Howell VM, Clarke SJ, Pavlakis N.

Asia Pac J Clin Oncol. 2018 Oct;14(5):e275-e282. doi: 10.1111/ajco.12877. Epub 2018 Apr 19.

PMID:
29675948
40.

External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review.

Chan DL, Thompson R, Lam M, Pavlakis N, Hallet J, Law C, Singh S, Myrehaug S.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):400-408. doi: 10.1016/j.clon.2018.03.006. Epub 2018 Mar 31.

PMID:
29615284
41.
42.

Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS).

Chan DL, Moody L, Segelov E, Metz DC, Strosberg JR, Pavlakis N, Singh S.

Neuroendocrinology. 2018;107(1):32-41. doi: 10.1159/000488394. Epub 2018 Mar 14.

PMID:
29539613
43.

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics.

Itchins M, Clarke S, Pavlakis N.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S39-S45. doi: 10.21037/tlcr.2018.01.06. No abstract available.

44.

Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer.

Lane RJ, Khin NY, Pavlakis N, Hugh TJ, Clarke SJ, Magnussen J, Rogan C, Flekser RL.

Future Oncol. 2018 Mar;14(7):647-663. doi: 10.2217/fon-2017-0546. Epub 2018 Mar 7.

45.

Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.

Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M.

Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1. Review.

PMID:
29478352
46.

Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.

Hayes AR, Brungs D, Pavlakis N.

PLoS One. 2018 Jan 25;13(1):e0191455. doi: 10.1371/journal.pone.0191455. eCollection 2018. Review.

47.

Convergent priorities and tensions: a qualitative study of the integration of complementary and alternative therapies with conventional cancer treatment.

River J, McKenzie H, Levy D, Pavlakis N, Back M, Oh B.

Support Care Cancer. 2018 Jun;26(6):1791-1797. doi: 10.1007/s00520-017-4021-0. Epub 2017 Dec 16.

PMID:
29249059
48.

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

Leyden J, Pavlakis N, Chan D, Michael M, Clarke S, Khasraw M, Price T.

Asia Pac J Clin Oncol. 2018 Jun;14(3):256-263. doi: 10.1111/ajco.12785. Epub 2017 Nov 6.

PMID:
29105989
49.

Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration.

Oh B, Eade T, Kneebone A, Hruby G, Lamoury G, Pavlakis N, Clarke S, Zaslawski C, Marr I, Costa D, Back M.

Integr Cancer Ther. 2018 Jun;17(2):458-466. doi: 10.1177/1534735417734912. Epub 2017 Nov 2.

50.

Bisphosphonates and other bone agents for breast cancer.

O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A.

Cochrane Database Syst Rev. 2017 Oct 30;10:CD003474. doi: 10.1002/14651858.CD003474.pub4. Review.

Supplemental Content

Loading ...
Support Center